Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 22Vitamin D Deficiency 3Osteoporosis 2Obesity 2Carcinoma, Intraductal, Noninfiltrating 2Triple Negative Breast Neoplasms 1Pathologic Processes 1Pain 1Osteoporosis Secondary 1Neuralgia 1Neoplasms by Site 1Neoplasms 1Musculoskeletal Diseases 1Locally Advanced Breast Cancer and Large Operable Breast Cancer 1Hyperplasia 1Breast Diseases 1Breast Carcinoma In Situ 1Biomarker Change Linked to Breast Cancer 1Arthralgia 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Cholecalciferol × Breast × Clear all
NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Wake Forest University Health Sciences

Phase 2 Recruiting
50 enrolled
Breast

Vitamin D Deficiency, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡